Cited by 381Multiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsBone health and treatments

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Open access

Richardson, Paul G., Siegel, David S., Vij, Ravi, Hofmeister, Craig C., Baz, Rachid, Jagannath, Sundar, Chen, Christine, Lonial, Sagar, Jakubowiak, Andrzej, Bahlis, Nizar, Song, Kevin, Belch, Andrew, Raje, Noopur, Shustik, Chaim, Lentzsch, Suzanne, Lacy, Martha, Mikhael, Joseph, Matous, Jeffrey, Vesole, David, Chen, Min, Zaki, Mohamed H., Jacques, Christian, Yu, Zhinuan, Anderson, Kenneth C.·2014·Blood

DOI 10.1182/blood-2013-11-538835PMC PMC3962162

Open this paper in CoChat — free account

Abstract

Key Points: Pomalidomide plus low-dose dexamethasone significantly improved PFS vs pomalidomide alone in relapsed and refractory multiple myeloma. Pomalidomide plus low-dose dexamethasone is an important new treatment option for RRMM patients who have received multiple prior therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood-2013-11-538835

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citation
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
Bladé, J., Samson, D., Reece, D. E., Apperley, J. F., Björkstrand, B., Gahrton, G., Gertz, M. A., Giralt, S. A., Jagannath, S., & Vesole, D. H. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,516
Self-citation
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citation
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citation
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
Hideshima, T., Chauhan, D., Shima, Y., Raje, N. S., Davies, F. E., Tai, Y., Treon, S. P., Lin, B. K., Schlossman, R. L., Richardson, P. G. G., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 874
Self-citation
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Palumbo, A. P., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G. G., Miguel, J. F. S., Barlogie, B., Harousseau, J., Zonder, J. A., Cavo, M., Zangari, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2405062 · Cited by 840
Self-citation
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Miguel, J. F. S., Weisel, K. C., Moreau, P., Lacy, M. Q., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 806
Self-citation
Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF-α
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 792
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L. M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · PubMed · Cited by 729
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Self-citation
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.12.4525 · Cited by 669
Self-citation
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
Siegel, D. S. D., Martin, T. G., Wang, M. L., Vij, R., Jakubowiak, A. J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N. J., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-425934 · Cited by 664
Self-citation
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
Quach, H., Ritchie, D., Stewart, A. K., Neeson, P. J., Harrison, S. J., Smyth, M. J., & Prince, H. M. (2009) · Leukemia · doi:10.1038/leu.2009.236 · Cited by 611
Clinical Course of Patients With Relapsed Multiple Myeloma
Kumar, S. K., Therneau, T. M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Rajkumar, S. V., Fonseca, R., Witzig, T. E., Lust, J. A., Larson, D. R., et al. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.867 · Cited by 365
Self-citation
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Lacy, M. Q., Hayman, S. R., Gertz, M. A., Dispenzieri, A., Buadi, F., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6802 · Cited by 317
Self-citation
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
Schey, S., Fields, P. A., Bartlett, J. B., Clarke, I., Ashan, G., Knight, R., Streetly, M. J., & Dalgleish, A. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.052 · Cited by 312
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2
Munshi, N. C., Anderson, K. C., Bergsagel, P. L., Shaughnessy, J. D., Palumbo, A. P., Durie, B. G. M., Fonseca, R., Stewart, A. K., Harousseau, J., Dimopoulos, M. A., et al. (2011) · Blood · doi:10.1182/blood-2010-10-300970 · Cited by 312
Self-citation
Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival
Avet‐Loiseau, H., Attal, M., Campion, L., Caillot, D., Hulin, C., Marit, G., Stoppa, A., Voillat, L., Wetterwald, M., Pegourié, B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5726 · Cited by 223
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
Lacy, M. Q., Allred, J. B., Gertz, M. A., Hayman, S. R., Short, K. D., Buadi, F., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348896 · Cited by 222
Self-citation
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02
Leleu, X. P., Attal, M., Arnulf, B., Moreau, P., Traullé, C., Marit, G., Mathiot, C., Petillon, M. O., Macro, M., Roussel, M., et al. (2013) · Blood · doi:10.1182/blood-2012-09-452375 · Cited by 206
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
Lacy, M. Q., Hayman, S. R., Gertz, M. A., Short, K. D., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2010) · Leukemia · doi:10.1038/leu.2010.190 · Cited by 197
Self-citation
Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism
Escoubet‐Lozach, L., Lin, I.-L., Jensen-Pergakes, K., Brady, H. A., Gandhi, A. K., Schafer, P. H., Muller, G. W., Worland, P. J., Chan, K. W. H., & Verhelle, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4898 · Cited by 173
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
Richardson, P. G. G., Siegel, D. S. D., Baz, R., Kelley, S. L., Munshi, N. C., Laubach, J. P., Sullivan, D. M., Alsina, M., Schlossman, R. L., Ghobrial, I. M., et al. (2012) · Blood · doi:10.1182/blood-2012-08-450742 · Cited by 162
Self-citation
New Drugs for Myeloma
Richardson, P. G. G., Mitsiades, C. S., Schlossman, R. L., Munshi, N. C., & Anderson, K. C. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-664 · Cited by 158
Self-citation
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
Anderson, G., Gries, M., Kurihara, N., Honjo, T., Anderson, J., Donnenberg, V. S., Donnenberg, A. D., Ghobrial, I. M., Mapara, M. Y., Stirling, D., et al. (2005) · Blood · doi:10.1182/blood-2005-08-3450 · Cited by 148
Self-citation
Treatment Options for Relapsed and Refractory Multiple Myeloma
Lonial, S., Mitsiades, C. S., & Richardson, P. G. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1805 · Cited by 126
Self-citation
Alternate day pomalidomide retains anti‐myeloma effect with reduced adverse events and evidence of in vivo immunomodulation
Streetly, M. J., Gyertson, K., Daniel, Y., Zeldis, J. B., Kazmi, M. A., & Schey, S. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07013.x · Cited by 125
Phase II Trials in Journal of Clinical Oncology
Cannistra, S. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1811 · Cited by 103
Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases
Xu, Y., Li, J., Ferguson, G. D., Mercurio, F., Khambatta, G., Morrison, L., Lopez‐Girona, A., Corral, L. G., Webb, D. R., Bennett, B. L., et al. (2009) · Blood · doi:10.1182/blood-2009-02-200543 · Cited by 88
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
Larocca, A., Montefusco, V., Bringhen, S., Rossi, D., Crippa, C., Mina, R., Galli, M., Marcatti, M., Verde, G. L., Giuliani, N., et al. (2013) · Blood · doi:10.1182/blood-2013-03-488676 · Cited by 85
Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications.
Hervé, A., Florence, M., Philippe, M., Michel, A., Thierry, F., Kenneth, A., Jean-Luc, H., Nikhil, M., & Stéphane, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8435 · Cited by 79
The use of novel agents in the treatment of relapsed and refractory multiple myeloma
Laubach, J. P., Mahindra, A. K., Mitsiades, C. S., Schlossman, R. L., Munshi, N. C., Ghobrial, I. M., Carreau, N. A., Hideshima, T., Anderson, K. C., & Richardson, P. G. G. (2009) · Leukemia · doi:10.1038/leu.2009.179 · Cited by 78
Self-citation
A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
Lilienfeld‐Toal, M. V., Hahn‐Ast, C., Furkert, K., Hoffmann, F., Naumann, R., Bargou, R. C., Cook, G., & Glasmacher, A. G. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01121.x · Cited by 78
Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis
Koh, K.-R. (2004) · Blood · doi:10.1182/blood-2004-03-0828 · Cited by 57
ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma
Mark, T. M., Rodriguez, M., Shah, M. B., Quinn, R., Campbell, J., Abdullah, R., Pearse, R. N., Zafar, F., Pekle, K. A., Mignott, P., et al. (2011) · Blood · doi:10.1182/blood.v118.21.635.635 · Cited by 42
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
Shah, J. J., Stadtmauer, E. A., Abonour, R., Cohen, A. D., Bensinger, W., Gasparetto, C., Kaufman, J. L., Lentzsch, S., Vogl, D. T., Orlowski, R. Z., et al. (2012) · Blood · doi:10.1182/blood.v120.21.74.74 · Cited by 31
Self-citation
ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma
Mark, T. M., Boyer, A. S., Rossi, A., Shah, M. B., Pearse, R. N., Zafar, F., Pekle, K. A., Tegnestam, L., Sacris, E., Greenberg, J., et al. (2012) · Blood · doi:10.1182/blood.v120.21.77.77 · Cited by 20
Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).
Vij, R., Richardson, P. G. G., Jagannath, S., Siegel, D. S. D., Baz, R., Srinivasan, S. S., Larkins, G., Zaki, M. H., Hussein, M. A., & Anderson, K. C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.8016 · Cited by 18
Self-citation
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma
Mark, T. M., Forsberg, P. A., Rossi, A., Pearse, R. N., Pekle, K. A., Perry, A., Boyer, A. S., Tegnestam, L., Jayabalan, D. S., Coleman, M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028027 · Cited by 16
Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma
Palumbo, A. P., Larocca, A., Montefusco, V., Rossi, D., Carella, A. M., Mina, R., Crippa, C., Sciacca, M., Galli, M., Scalabrini, D. R., et al. (2012) · Blood · doi:10.1182/blood.v120.21.446.446 · Cited by 14
Oral Weekly Cyclophosphamide in Combination with Pomalidomide and Dexamethasone for Relapsed and Refractory Myeloma: Report of the Dose Escalation Cohort
Baz, R., Shain, K. H., Alsina, M., Nardelli, L. A., Nishihori, T., Ochoa, L., Martin, T. G., Jagannath, S., Dalton, W. S., & Sullivan, D. M. (2012) · Blood · doi:10.1182/blood.v120.21.4062.4062 · Cited by 13
Self-citation
A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma.
Berenson, J. R., Hilger, J. D., Klein, L. M., Eshaghian, S., Nassir, Y., Swift, R. A., & Vescio, R. A. (2012) · Blood · doi:10.1182/blood.v120.21.2979.2979 · Cited by 12
MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
Richardson, P. G. G., Hofmeister, C. C., Siegel, D. S. D., Lonial, S., Zaki, M. H., Ye, H., Shah, S., Wang, J., & Anderson, K. C. (2012) · Blood · doi:10.1182/blood.v120.21.727.727 · Cited by 12
Self-citation
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943.h8002943_2943_2950
Self-citation

Research works printed but not linked: 1

Rychack, 2011, Overcoming resistance; the use of pomalidomide (POM) and dexamethasone (DEX) in re-sensitizing lenalidomide (LEN)-resistant multiple myeloma (MM) cells., Haematologica, 96, S126

Sorted by citations

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
Self-citation
Diagnosis and Management of Multiple Myeloma
Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L., Tuazon, S. A., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,082
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854
Self-citation
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812

See all 381

Authors: Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., Song, K., Belch, A., Raje, N., Shustik, C., Lentzsch, S., Lacy, M., Mikhael, J., Matous, J., Vesole, D., Chen, M., Zaki, M. H., Jacques, C., Yu, Z., & Anderson, K. C.
Affiliations: Dana-Farber Cancer Institute (US)
Hackensack University Medical Center (US)
Washington University in St. Louis (US)
The Ohio State University (US)
Moffitt Cancer Center (US)
Mount Sinai Medical Center, New York, NY;
Princess Margaret Cancer Centre (CA)
Emory University (US)
University of Chicago Medical Center (US)
University of Calgary (CA)
Vancouver General Hospital (CA)
University of Alberta (CA)
Massachusetts General Hospital (US)
Royal Victoria Hospital (CA)
Columbia University (US)
Mayo Clinic (US)
Colorado Blood Cancer Institute (US)
Celgene (United States) (US)
ORCID: Richardson, Paul G.
Siegel, David S.
Vij, Ravi
Hofmeister, Craig C.
Baz, Rachid
Jagannath, Sundar
Chen, Christine
Lonial, Sagar
Jakubowiak, Andrzej
Bahlis, Nizar
Song, Kevin
Belch, Andrew
Raje, Noopur
Lentzsch, Suzanne
Lacy, Martha
Mikhael, Joseph
Vesole, David
Chen, Min
Jacques, Christian
Anderson, Kenneth C.
Venue: Blood
Publisher: American Society of Hematology
Published: 2014-03-20
Volume: 123
Issue: 12
Pages: 1826-1832
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2013-11-538835
PMC: PMC3962162
OpenAlex: W2091773528
Cited by: 381
References: 43
Citations by year: 2026: 7 · 2025: 11 · 2024: 17 · 2023: 14 · 2022: 39 · 2021: 30 · 2020: 31 · 2019: 24 · 2018: 30 · 2017: 54 · 2016: 48 · 2015: 48 · 2014: 27
FWCI: 41.83
Type: journal article
Language: en
Update notices: erratum (2014-05-15)
Open access: green
www.ncbi.nlm.nih.gov
Locations: Blood (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Celgene
National Cancer Institute (P50CA100707, P01CA155258, P30CA016058)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords: pomalidomide, low-dose dexamethasone, relapsed/refractory multiple myeloma, progression-free survival, lenalidomide-refractory disease, bortezomib resistance, combination therapy, neutropenia, peripheral neuropathy, overall survival, overall response rate
MeSH terms: Bortezomib, Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Boronic Acids, Dexamethasone, Female, Humans, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Neutropenia, Pyrazines, Thalidomide, Treatment Outcome, Disease-Free Survival, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks